Product Name | Ruxolitinib |
Description |
JAK kinase inhibitor |
Purity | >98% |
CAS No. | 941678-49-5 |
Molecular Formula | C17H18N6 |
Molecular Weight | 306.4 |
Field of Use | Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only. |
Storage Temperature | -20ºC |
Shipping Temperature | Shipped Ambient |
Product Type | Inhibitor |
Solubility | Soluble in DMSO (25 mg/ml) or EtOH (~15 mg/ml) |
Source | Synthetic |
Appearance | Off-white solid |
SMILES | C1CCC(C1)[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3 |
InChI | InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1 |
InChIKey | HFNKQEVNSGCOJV-OAHLLOKOSA-N |
Safety Phrases |
Classification: Skin Corrosion/Irritation, Category 2 Serious Eye Damage/Eye Irritation, Category 1 Danger Target Organ Systemic Toxicity (repeated exposure), Category 2 Toxic To Reproduction, Category 2 Warning Acute Toxicity: Oral, Category 4 Safety Phrases: S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. Hazard statements: H315: Causes skin irritation. H318: Causes serious eye damage H373: May cause damage to organs through prolonged or repeated exposure. H361: Suspected of damaging fertility or the unborn child. H302: Harmful if swallowed. Precautionary statements: P264: Wash hands thoroughly after handling. P280: Wear protective gloves/clothing and eye/face protection as specified by the manufacturer/supplier or the competent authority. P260: Do not breathe dust/fume/gas/mist/vapours/spray. P201: Obtain special instructions before use. P202: Do not handle until all safety precautions have been read and understood. P281: Use personal protective equipment as required. P302+352: IF ON SKIN: Wash with plenty of soap and water. P332+313: If skin irritation occurs, get medical advice/attention. P362: Take off contaminated clothing and wash before re-use. P305+351+338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P310: Immediately call a POISON CENTER or doctor/physician. P314: Get medical attentiodvice if you feel unwell. P308+313: IF exposed or concerned: Get medical attentiodvice. P301+312: IF SWALLOWED: Call a POISON CENTER or doctor/physician if you feel unwell. P330: Rinse mouth. |
Cite This Product | Ruxolitinib (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-509) |
Alternative Names | (3R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Research Areas | Apoptosis, Cancer, Cancer Growth Inhibitors, Cell Signaling, Tyrosine Kinase Inhibitors |
PubChem ID | 25126798 |
Scientific Background | Ruxolitinib is a selective inhibitor of Janus-associated kinases (JAK1 and JAK2), key mediators in cytokine signaling pathways. While primarily developed for hematologic malignancies and inflammatory disorders, Ruxolitinib has gained attention in neurodegenerative disease research due to its ability to modulate neuroinflammation. Dysregulated JAK/STAT signaling is implicated in several neurodegenerative conditions, including Alzheimer's and Parkinson's disease. By suppressing pro-inflammatory cytokine signaling, Ruxolitinib may reduce microglial activation and neuronal damage. Its potential to cross the blood-brain barrier further supports its exploration as a neuroprotective agent. |
References | 1. Aittomäki S., & Pesu M. (2014) Basic & Clin. Pharm.Toxic. 114(1): 18–23. |
Reviews
There are no reviews yet.